



Your link to the latest news on research, treatment, prevention and education from the state's only National Cancer Institute - designated Comprehensive Cancer Center

CINJ and RWJUH to Host Free Prostate Cancer Screenings

The American Cancer Society estimates that 192,000 new cases of prostate cancer will occur in the U.S. this year, with over 5,000 new cases diagnosed in New Jersey. It is those statistics The Cancer Institute of New Jersey (CINJ) and its flagship hospital, Robert Wood Johnson University Hospital (RWJUH) hope to tackle by hosting their annual prostate cancer screening event this month, which is National Prostate Cancer Awareness Month. A team of physicians from the Dean and Betty Gallo Prostate Cancer Center at CINJ will be conducting the screenings September 21, 22, and 23, from 5:00pm to 8:00pm each evening at CINJ in New Brunswick. The free event, which will include a digital rectal exam and the prostate specific antigen (PSA) blood test, is open to all men 40 years and older. Appointments are necessary and can be made by calling 732-247-2050.

CINJ Welcomes Mountainside Hospital as its Newest Affiliate

Enhancing its strong presence as a statewide leader in cancer care and providing patients with additional access to cancer programs, The Cancer Institute of New Jersey Network of hospitals has formally welcomed Mountainside Hospital as its newest Clinical Research Affiliate. The Montclair-based facility owned by Merit Health Systems is now the 16th affiliate hospital of CINJ. As a Clinical Research Affiliate, Mountainside Hospital is able to offer its patients enrollment in CINJ clinical trials while having them receive care and treatment locally at the Montclair facility. Mountainside patients also will receive access to community education, outreach and other services provided by CINJ that complement the hospital's comprehensive cancer program. Mountainside Hospital President and CEO John Fromhold says expanding patient access at those levels will only enhance the hospital's commitment to excellence in its cancer service line.

Researchers at CINJ Awarded \$5M in State Funding

As part of its mission to advance cancer research, The New Jersey Commission on Cancer Research (NJCCR) recently awarded \$10 million in competitive grants to investigators throughout the state including a number of scientists at The Cancer Institute of New Jersey. CINJ was awarded approximately \$5.1 million, of which, \$3.6 million is comprised of New Jersey Cancer Research Development Awards designed to strengthen cancer research infrastructure in the state through shared resources, multidisciplinary research networks, and state of the art equipment. CINJ scientists have forged new and innovative partnerships with other New Jersey academic centers, laying the groundwork for some very exciting "team" approaches in these grants. The remainder of the funds are designated as Seed Grants, which support new investigators in becoming established in New Jersey, assist established scientists looking for new directions in cancer research and encourage promising and novel translational, epidemiological and clinical studies. According to NJCCR, the awards are given through an open and competitive grant program, based on a National Institutes of Health system of scientific review that is available to all non-profit research institutions, cancer centers hospitals or scientific agencies in New Jersey that meet the minimum eligibility requirements.

Honorees Announced for 14th Annual Award of Hope Gala and Benefit Auction

"A cure for cancer won't happen by chance." That reminder from the Cancer Institute of New Jersey Foundation serves as the theme for its 14th Annual Award of Hope Gala and Benefit Auction, which will recognize pillars of New Jersey's cancer community this fall. The October 3rd Monte Carlo-themed affair at the Hyatt Regency in New Brunswick, will honor two individuals for their significant contributions to CINJ. The Award of Hope was established in 1997 to recognize those who have demonstrated untiring leadership and a deep commitment to serving the cancer needs of the people of New Jersey. This year's Award of Hope honoree is Sheri S. McCoy, worldwide chairman of Johnson & Johnson's Pharmaceuticals Group and a member of Johnson & Johnson's Executive Committee. Ms. McCoy's dedication to the cause of cancer, both personally and as a corporate executive and organizational leader for Johnson & Johnson employees, has a profound effect that extends well beyond the borders of New Jersey. The Award for Leadership in Patient Care will also be presented during the event to acknowledge the health care professional whose life and work exemplify the spirit and mission of CINJ. This year's award will be given to Darlene G. Gibbon, MD, clinical director of gynecologic oncology at CINJ and assistant professor of Obstetrics, Gynecology & Reproductive Sciences at UMDNJ-Robert Wood Johnson Medical School. She has focused on providing her patients with the most comprehensive cancer care since her arrival in 2000. She also has championed services and support for cancer patients in their late teens and twenties -- a unique population that has numerous unmet needs in relation to cancer care and survivorship. By supporting and recognizing the enormous contributions of distinguished corporations and private citizens, it is the CINJ Foundation's goal to nourish the spirit of advocacy and philanthropy throughout the state. For sponsorship and ticket information for the Award of Hope Gala and Benefit Auction, visit www.cinjfoundation.org or call 732-235-4956.



ROBERT WOOD JOHNSON
MEDICAL SCHOOL
University of Medicine & Dentistry of New Jersey

195 Little Albany Street • New Brunswick, NJ • Office of Communications 732/235-9891 • www.cinj.org

